TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19432546

Group type: EXPERIMENTAL
Intervention: Maraviroc once daily
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Maraviroc twice daily
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 16750963

Group type: EXPERIMENTAL
Intervention: Regular NSAID use (any NSAID) for 5 or more years
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Regular non-aspirin NSAID use
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Any NSAID use
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Duration of regular NSAID use
Number of subjects: 22071
Study: 12745496

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 11056754

Group type: EXPERIMENTAL
Intervention: Tonometered saline PCO2 measurement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gastric juice PCO2 measurement
Number of subjects: 15
Study: 8989129

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Couplets
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Couplets and/or NSVT (ventricular repetitive beats)
Number of subjects: 516
Study: 1536472

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (2 x 600 mg oral per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6387988

Group type: EXPERIMENTAL
Intervention: A/S
Number of subjects: 57

Group type: COMPARATOR
Intervention: NI: ASA
Number of subjects: 57
Study: 31562405

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 120

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 120
Study: 28341838

Group type: EXPERIMENTAL
Intervention: Functional Generated Path (FGP) technique
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Average-value FGP technique (AVR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional fabrication (CON)
Number of subjects: 10
Study: 25833669

Group type: EXPERIMENTAL
Intervention: Polyamine-reduced diet (PRD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal polyamine containing diet
Number of subjects: 80
Study: 23638711

Group type: EXPERIMENTAL
Intervention: Breastfeeding counselling (BFC)
Number of subjects: 3214

Group type: COMPARATOR
Intervention: Usual/standard health message (UHM)
Number of subjects: 3214

Group type: EXPERIMENTAL
Intervention: Prenatal multiple micronutrients combined with BFC
Number of subjects: 3214

Group type: COMPARATOR
Intervention: Prenatal 60 mg iron and folate combined with UHM
Number of subjects: 3214

Group type: COMPARATOR
Intervention: BFC vs UHM
Number of subjects: 3214
Study: 20702514

Group type: EXPERIMENTAL
Intervention: Craniosacral therapy for 20 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham treatment with disconnected magnetotherapy equipment for 20 weeks
Number of subjects: 92
Study: 19879226

Group type: EXPERIMENTAL
Intervention: RotaTeq vaccine
Number of subjects: 2686

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2686
Study: 17117100

Group type: EXPERIMENTAL
Intervention: Topical betacaine application
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical betacaine followed by skin cooling
Number of subjects: 40
Study: 15265098

Group type: EXPERIMENTAL
Intervention: Helping during treatment
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: 12‐step involvement
Number of subjects: 279
Study: 11933878

Group type: EXPERIMENTAL
Intervention: Single dose of steroids (oral or intramuscular dexamethasone, 0.6 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroid therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroids in pharyngitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose and short-term steroid therapy (less than a week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine use of steroids for recurrent ENT infections
Number of subjects: 0
Study: 9640129

Group type: EXPERIMENTAL
Intervention: Patient education program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sulphasalazine therapy
Number of subjects: 60
Study: 8115611

Group type: EXPERIMENTAL
Intervention: CT at 80 mAs (experimental group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: CT at 240 mAs (control group)
Number of subjects: 78
Study: 2680431

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 174

Group type: COMPARATOR
Intervention: Vitamin K
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Propranolol (without ascites)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Propranolol (with ascites)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Vitamin K (with ascites)
Number of subjects: 174
Study: 1093427

Group type: EXPERIMENTAL
Intervention: Oral administration of 10 mg diazepam
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intramuscular injection into the thigh of 10 mg diazepam
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intramuscular injection into the buttock of 10 mg diazepam
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Oral and thigh routes of administration
Number of subjects: 1
Study: 31704126

Group type: EXPERIMENTAL
Intervention: Early pacifier use recommendation
Number of subjects: 239

Group type: COMPARATOR
Intervention: Avoid pacifier use during the first two weeks
Number of subjects: 239
Study: 30928344

Group type: EXPERIMENTAL
Intervention: PALS
Number of subjects: 104

Group type: COMPARATOR
Intervention: WebMD
Number of subjects: 104
Study: 27992949

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing for phenprocoumon in younger patients (< 75 years)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing for phenprocoumon in older patients (≥ 75 years)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Acenocoumarol users with genotype-guided dosing
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group for younger patients (< 75 years)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group for older patients (≥ 75 years)
Number of subjects: 142
Study: 25971907

Group type: EXPERIMENTAL
Intervention: Obatoclax (20 mg/m2) in combination with fludarabine and rituximab (FR)
Number of subjects: 13
Study: 23073215

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 23
Study: 21515995

Group type: EXPERIMENTAL
Intervention: Hospice Smart Patient Service (face-to-face or phone) at least once a week for 5 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17658633

Group type: EXPERIMENTAL
Intervention: Bosentan (62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (ex-placebo group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (ex-bosentan and ex-placebo)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 37
Study: 17053955

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 8 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluoxetine and Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 18
Study: 14689888

Group type: EXPERIMENTAL
Intervention: DBTC catheter (transurethral perfusion and drainage with antibiotics)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 103

Group type: COMPARATOR
Intervention: 0.9% saline (transurethral irrigation)
Number of subjects: 103
Study: 10530851

Group type: EXPERIMENTAL
Intervention: Low-energy shock waves
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: High-energy shock waves (one session)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: High-energy shock waves (two sessions)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study: 8742456

Group type: EXPERIMENTAL
Intervention: Schizophrenia subjects
Number of subjects: 51

Group type: COMPARATOR
Intervention: Unaffected individuals
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Schizophrenia-related illness subjects or obligate carriers
Number of subjects: 51
Study: 2024959

Group type: EXPERIMENTAL
Intervention: GR69153
Number of subjects: 0
Study: 6118521

Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) imaging
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cranial X-ray computed tomography (CT)
Number of subjects: 10
Study: 6143042

Group type: EXPERIMENTAL
Intervention: Live attenuated cold‐adapted reassortant influenza virus vaccine (10(7.5) TCID50, intranasally)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Inactivated vaccine (administered intramuscularly)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Live attenuated cold‐adapted reassortant influenza virus vaccine (10(7.5) TCID50)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Inactivated vaccine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Live attenuated cold‐adapted reassortant influenza virus vaccine
Number of subjects: 81
Study: 28843034

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (2 face-to-face and 5 telephone counselling sessions)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 59
Study: 27752167

Group type: EXPERIMENTAL
Intervention: CHOPE+L-asparaginase (L-ASP) regimen
Number of subjects: 61

Group type: COMPARATOR
Intervention: CHOPE regimen
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall survival rates in CHOPE+L
Number of subjects: 61

Group type: COMPARATOR
Intervention: Overall survival rates in CHOPE
Number of subjects: 61
Study: 24103693

Group type: EXPERIMENTAL
Intervention: Children with social phobia (anxiety induced)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Children with social phobia (no anxiety induction)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control children (anxiety induced)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control children (no anxiety induction)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Self-report measures of anxiety
Number of subjects: 73
Study: 22041866

Group type: EXPERIMENTAL
Intervention: mIL‐11 (7.5 μg/kg/day) for 10 days, beginning 72 h after chemotherapy (cycle-1)
Number of subjects: 88

Group type: COMPARATOR
Intervention: rhIL‐11 (25 μg/kg/day) for 10 days (cycle-2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: mIL‐11
Number of subjects: 88

Group type: COMPARATOR
Intervention: rhIL‐11
Number of subjects: 88

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 88
Study: 20215823

Group type: EXPERIMENTAL
Intervention: Antibiotics (Group 1)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control (Group 3)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: EPS-Antibiotics (Group 4)
Number of subjects: 216
Study: 17661724

Group type: EXPERIMENTAL
Intervention: Test formulation (Aurene, 600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation (Trileptal, 600 mg)
Number of subjects: 12
Study: 16160416

Group type: EXPERIMENTAL
Intervention: 1.5 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 1.0 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 0.8 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Number of subjects: 93
Study: 12006922

Group type: EXPERIMENTAL
Intervention: Randomized, controlled trials published in 2000
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Randomized, controlled trials published in 1995
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Randomized, controlled trials published in 1990
Number of subjects: 17

Group type: COMPARATOR
Intervention: Other journals evaluated (Annals of Surgery, Archives of Surgery, Gastroenterology)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Statistical power calculations
Number of subjects: 17
Study: 10630264

Group type: EXPERIMENTAL
Intervention: Poisoning-related visits to emergency departments
Number of subjects: 100000000

Group type: EXPERIMENTAL
Intervention: Poisoning-related visits
Number of subjects: 100000000

Group type: COMPARATOR
Intervention: Illness visits
Number of subjects: 100000000

Group type: COMPARATOR
Intervention: Nonpoisoning-related injury visits
Number of subjects: 100000000
Study: 8562661

Group type: EXPERIMENTAL
Intervention: Transplantation of human fetal mesencephalic tissue
Number of subjects: 9
Study: 1824143

Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g 4 times a day (Group 1)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Famotidine, 40 mg single evening dose (Group 2)
Number of subjects: 79
Study: 6242957

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Naproxen 250 mg bid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 60
Study: 30985539

Group type: EXPERIMENTAL
Intervention: Active warming group (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 50
Study: 29601316

Group type: EXPERIMENTAL
Intervention: Diazoxide (200-400 mg daily, twice a day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 25771490

Group type: EXPERIMENTAL
Intervention: Capsaicin (5 mg/d)
Number of subjects: 44
Study: 24725805

Group type: EXPERIMENTAL
Intervention: Oral α‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 22295812

Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture and medicine (heat-producing needling at Pishu (BL 20) and Zhishi (BL 52) with Terazosin Hydrochloride, Bisoprolol Fumarate tablets, or compound Reserpinum Triamterene tablet for high blood pressure)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Medicine group I (Renin‐Angiotensin‐Aldosterone system interruption with Benazepril Hydrochloride and Telmisartan for blood pressure control)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Medicine group II (placebo with same medicine therapy as combined therapy for high blood pressure)
Number of subjects: 240
Study: 21269039

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride dentifrice
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride, sodium hexametaphosphate, and zinc lactate dentifrice
Number of subjects: 171

Group type: COMPARATOR
Intervention: 0.243% sodium fluoride dentifrice
Number of subjects: 171
Study: 17703390

Group type: COMPARATOR
Intervention: Propofol alone (Group A)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Sedato-analgesic cocktail (midazolam, ketamine, pentazocine plus propofol) (Group B)
Number of subjects: 199
Study: 15640455

Group type: EXPERIMENTAL
Intervention: Regular meal pattern (6 occasions/d)
Number of subjects: 10
Study: 12394941

Group type: EXPERIMENTAL
Intervention: 25 g of human serum albumin every 8 hrs with continuous infusion furosemide
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dual placebo
Number of subjects: 37
Study: 10337446

Group type: EXPERIMENTAL
Intervention: St. John's wort extract LoHyp-57 (800 mg daily)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: St. John's wort extract LoHyp-57
Number of subjects: 149

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 149
Study: 7856515

Group type: EXPERIMENTAL
Intervention: Acid aerosol (10 microM MMAD H2SO4, pH 2.0, 500 micrograms/m3)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control aerosol (equiosmolar NaCl)
Number of subjects: 7
Study: 1780996

Group type: EXPERIMENTAL
Intervention: Ivermectin (100 micrograms/kg, single dose)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (3 mg/kg for one day, then 6 mg/kg daily for 12 d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 7174860

Group type: EXPERIMENTAL
Intervention: Metoclopramide (40 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Metoclopramide (60 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 30306731

Group type: EXPERIMENTAL
Intervention: Six-gene signature (CTSW, PCSK4, LRRC8D, TNFRSF18, IHH, and CDKN2A) developed using multivariate Cox proportional hazard regression.
Number of subjects: 0
Study: 29178717

Group type: EXPERIMENTAL
Intervention: Replacement of brush head every 4 weeks (R)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-replacement of brush head over 6 months (NR)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sonic action toothbrushes in NR group
Number of subjects: 49
Study: 24485398

Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 21895786

Group type: EXPERIMENTAL
Intervention: Dermasilk® briefs
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cotton placebo briefs
Number of subjects: 96
Study: 20300631

Group type: EXPERIMENTAL
Intervention: Routine HIV-1 viral load (VL) monitoring at ART-initiation and at 3, 6, 12, and 18 months
Number of subjects: 1973

Group type: COMPARATOR
Intervention: Local standard of care (immunological and clinical criteria for treatment failure, discretionary VL testing)
Number of subjects: 1973
Study: 17595353

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 49

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 49
Study: 16371798

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sodium hyaluronate
Number of subjects: 52
Study: 11926713

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge with concomitant antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9807204

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (no radiotherapy)
Number of subjects: 360
Study: 8082521

Group type: EXPERIMENTAL
Intervention: Ultralente insulin (Humulin U)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermediate insulin (Humulin I)
Number of subjects: 16
Study: 2554837

Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg/day (beta-blocker)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30596812

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/cetuximab (PCC)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin/5-fluorouracil/cetuximab (C-TPF)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Historical control from RTOG-0129
Number of subjects: 136
Study: 27055279

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (0.26 μg/kg/h)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (2.0 μg/kg/h)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 13
Study: 25151916

Group type: EXPERIMENTAL
Intervention: Combination treatment (PE plus sertraline)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Prolonged exposure (PE)
Number of subjects: 642
Study: 22510805

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity walking program (70% HRR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-intensity walking program (30% HRR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both groups (LI and VI)
Number of subjects: 44
Study: 20348496

Group type: EXPERIMENTAL
Intervention: 30 mg primaquine daily for 7 days
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 60 mg primaquine daily for 7 days
Number of subjects: 85

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 85
Study: 18053592

Group type: EXPERIMENTAL
Intervention: Carvedilol (n=44)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 74
Study: 17111584

Group type: EXPERIMENTAL
Intervention: Multidetector helical computed tomography (MDCT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 23
Study: 12820784

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 11763946

Group type: EXPERIMENTAL
Intervention: Plasma arc curing (P)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Halogen light curing (H)
Number of subjects: 16
Study: 9011483

Group type: EXPERIMENTAL
Intervention: 5 MU interferon (IFN)-alpha2b three times a week for six months
Number of subjects: 230

Group type: COMPARATOR
Intervention: 3 MU interferon (IFN)-alpha2b three times a week for six months
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 3 MU interferon (IFN)-alpha2b three times a week for two years
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Two years of IFN therapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Continuing IFN therapy for at least 12 months
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Initial IFN treatment courses of 24 months
Number of subjects: 230
Study: 7961557

Group type: EXPERIMENTAL
Intervention: Clozapine concentration > 420 ng/mL
Number of subjects: 58

Group type: COMPARATOR
Intervention: Clozapine concentration < 420 ng/mL
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Clozapine concentration > 420 ng/mL at Week 12
Number of subjects: 58

Group type: COMPARATOR
Intervention: Clozapine concentration < 420 ng/mL at Week 12
Number of subjects: 58
Study: 2965438

Group type: EXPERIMENTAL
Intervention: 6-month interval worming with levamisole
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 12-month interval worming with levamisole
Number of subjects: 50
Study: 29873009

Group type: EXPERIMENTAL
Intervention: TAF/TIM
Number of subjects: 115

Group type: COMPARATOR
Intervention: LAT/TIM
Number of subjects: 115
Study: 28319109

Group type: EXPERIMENTAL
Intervention: Whole food plant-based (WFPB) diet with vitamin B12 supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 65
Study: 26771267

Group type: EXPERIMENTAL
Intervention: IV dexamethasone (0.5 mg/kg in 5 mL saline)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (5 mL IV saline)
Number of subjects: 60
Study: 23570591

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (U group, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nerve stimulation (N group, n = 30)
Number of subjects: 60